PMID- 23867634
OWN - NLM
STAT- MEDLINE
DCOM- 20140219
LR  - 20161125
IS  - 1421-9794 (Electronic)
IS  - 0009-3157 (Linking)
VI  - 59
IP  - 1
DP  - 2013
TI  - Successful everolimus treatment in a patient with advanced pancreatic 
      neuroendocrine tumor who developed everolimus-induced interstitial lung disease 
      on two occasions: a case report.
PG  - 74-8
LID - 10.1159/000351103 [doi]
AB  - Chemotherapy-associated interstitial lung disease (ILD) is often fatal, and the 
      chemotherapeutic regimen generally cannot be resumed. ILD associated with the 
      mammalian target of rapamycin (mTOR) inhibitor everolimus has many features 
      distinct from chemotherapy-associated ILD. We present the case of a 58-year-old 
      woman with an advanced pancreatic neuroendocrine tumor with liver metastases, in 
      whom everolimus treatment was maintained and resulted in a partial response 
      despite two occurrences of everolimus-induced ILD during a 31-month treatment 
      period until disease progression. Physicians treating with everolimus should 
      monitor patients closely for ILD and should apply appropriate management 
      strategies to optimize the possibility of maintaining everolimus therapy.
CI  - (c) 2013 S. Karger AG, Basel.
FAU - Nakayama, Yusuke
AU  - Nakayama Y
AD  - Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center 
      Hospital East, Kashiwa, Japan.
FAU - Ikeda, Masafumi
AU  - Ikeda M
FAU - Kojima, Motohiro
AU  - Kojima M
FAU - Goto, Koichi
AU  - Goto K
FAU - Hara, Miyuki
AU  - Hara M
FAU - Okuyama, Hiroyuki
AU  - Okuyama H
FAU - Takahashi, Hideaki
AU  - Takahashi H
FAU - Ohno, Izumi
AU  - Ohno I
FAU - Shimizu, Satoshi
AU  - Shimizu S
FAU - Mitsunaga, Shuichi
AU  - Mitsunaga S
FAU - Okusaka, Takuji
AU  - Okusaka T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130718
PL  - Switzerland
TA  - Chemotherapy
JT  - Chemotherapy
JID - 0144731
RN  - 0 (Antineoplastic Agents)
RN  - 0 (MUC1 protein, human)
RN  - 0 (Mucin-1)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - C-Reactive Protein/analysis
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/pathology/secondary
MH  - Lung Diseases, Interstitial/*chemically induced/diagnostic imaging/metabolism
MH  - Middle Aged
MH  - Mucin-1/blood
MH  - Neoplasm Staging
MH  - Neuroendocrine Tumors/*drug therapy
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - Tomography, X-Ray Computed
EDAT- 2013/07/23 06:00
MHDA- 2014/02/20 06:00
CRDT- 2013/07/23 06:00
PHST- 2012/10/16 00:00 [received]
PHST- 2013/03/26 00:00 [accepted]
PHST- 2013/07/23 06:00 [entrez]
PHST- 2013/07/23 06:00 [pubmed]
PHST- 2014/02/20 06:00 [medline]
AID - 000351103 [pii]
AID - 10.1159/000351103 [doi]
PST - ppublish
SO  - Chemotherapy. 2013;59(1):74-8. doi: 10.1159/000351103. Epub 2013 Jul 18.